Agennix AG to Present at BioEquity Conference
(Thomson Reuters ONE) -
Agennix AG / Agennix AG to Present at BioEquity Conference processed and transmitted by Hugin AS. The issuer is solely responsible for the content of this announcement.
Martinsried/Munich (Germany), Princeton, NJ and Houston, TX, May 14, 2010 -
Agennix AG (Frankfurt Stock Exchange: AGX) today announced that the Company will
give a corporate presentation at the upcoming BioEquity Europe 2010 conference.
The presentation will be held at 12 PM CET on Thursday, May 20, 2010 in Zurich,
Switzerland.
About Agennix
Agennix AG is a publicly traded biopharmaceutical company that is focused on the
development of novel therapies to improve the length and quality of life of
seriously ill patients in areas of major unmet medical need. The Company's most
advanced program is talactoferrin, an oral therapy that has demonstrated
activity in randomized, double-blind, placebo-controlled Phase II studies in
non-small cell lung cancer, as well as in severe sepsis. Talactoferrin is
currently in Phase III clinical trials in non-small cell lung cancer, and
Agennix plans to develop this program further for the treatment of severe
sepsis. Other clinical development programs include RGB-286638, a multi-targeted
kinase inhibitor in Phase 1 testing; the oral platinum-based compound
satraplatin; and a topical gel form of talactoferrin for diabetic foot ulcers.
Agennix's registered seat is in Heidelberg, Germany. The Company has three sites
of operation: Martinsried/Munich, Germany; Princeton, New Jersey and Houston,
Texas. For additional information, please visit the Agennix Web site at
www.agennix.com.
This press release contains forward-looking statements, which express the
current beliefs and expectations of the management of Agennix AG. Such
statements are based on current expectations and are subject to risks and
uncertainties, many of which are beyond our control, that could cause future
results, performance or achievements to differ significantly from the results,
performance or achievements expressed or implied by such forward-looking
statements. Actual results could differ materially depending on a number of
factors, and we caution investors not to place undue reliance on the
forward-looking statements contained in this press release. Forward-looking
statements speak only as of the date on which they are made and Agennix
undertakes no obligation to update these forward-looking statements, even if new
information becomes available in the future.
For further information, please contact:
Agennix
AG
Investor Relations & Corporate Communications
Phone: +49 (0)89 8565 2693
ir(at)agennix.com
In the U.S.: Laurie
Doyle
Director, Investor Relations & Corporate Communications
Phone: +1 609 524 5884
laurie.doyle(at)agennix.com
Additional media contacts for Europe:
MC Services
AG
Phone: +49 (0) 89 210 228 0
Raimund
Gabriel
raimund.gabriel(at)mc-services.eu
Hilda
Juhasz
hilda.juhasz(at)mc-services.eu
Additional investor contact for Europe:
Trout International
LLC
Lauren Williams, Vice President
Phone: +44 207 936 9325
lwilliams(at)troutgroup.com
[HUG#1415942]
--- End of Message ---
Agennix AG
Im Neuenheimer Feld 515 Heidelberg Germany
ISIN: DE000A1A6XX4;
Listed: Prime Standard in Frankfurter Wertpapierbörse,
Regulierter Markt in Frankfurter Wertpapierbörse;
Datum: 14.05.2010 - 15:02 Uhr
Sprache: Deutsch
News-ID 20912
Anzahl Zeichen: 0
contact information:
Town:
Heidelberg
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 269 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"Agennix AG to Present at BioEquity Conference"
steht unter der journalistisch-redaktionellen Verantwortung von
Agennix AG (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
